These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22891821)

  • 1. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.
    Ebdrup BH; Knop FK; Ishøy PL; Rostrup E; Fagerlund B; Lublin H; Glenthøj B
    BMC Med; 2012 Aug; 10():92. PubMed ID: 22891821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.
    Mayfield K; Siskind D; Winckel K; Russell AW; Kisely S; Smith G; Hollingworth S
    J Psychopharmacol; 2016 Mar; 30(3):227-36. PubMed ID: 26801056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
    Horska K; Ruda-Kucerova J; Skrede S
    Trends Endocrinol Metab; 2022 Sep; 33(9):628-638. PubMed ID: 35902330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
    Ishøy PL; Knop FK; Vilsbøll T; Glenthøj BY; Ebdrup BH
    Am J Psychiatry; 2013 Jun; 170(6):681-2. PubMed ID: 23732970
    [No Abstract]   [Full Text] [Related]  

  • 6. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.
    Marteene W; Winckel K; Hollingworth S; Kisely S; Gallagher E; Hahn M; Ebdrup BH; Firth J; Siskind D
    Expert Opin Drug Saf; 2019 Dec; 18(12):1149-1160. PubMed ID: 31564170
    [No Abstract]   [Full Text] [Related]  

  • 8. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 agonists for metabolic disorders in schizophrenia.
    Kouidrat Y; Amad A
    Schizophr Res; 2019 Feb; 204():448-449. PubMed ID: 30243855
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight gain from novel antipsychotic drugs: need for action.
    Green AI; Patel JK; Goisman RM; Allison DB; Blackburn G
    Gen Hosp Psychiatry; 2000; 22(4):224-35. PubMed ID: 10936629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments.
    Das C; Mendez G; Jagasia S; Labbate LA
    Ann Clin Psychiatry; 2012 Aug; 24(3):225-39. PubMed ID: 22860242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of antipsychotic-associated weight gain.
    O'Keefe CD; Noordsy DL; Liss TB; Weiss H
    J Clin Psychiatry; 2003 Aug; 64(8):907-12. PubMed ID: 12927005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
    Khan AY; Macaluso M; McHale RJ; Dahmen MM; Girrens K; Ali F
    J Psychiatr Pract; 2010 Sep; 16(5):289-96. PubMed ID: 20859106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine.
    Klemettilä JP; Solismaa A; Seppälä N; Hämäläinen M; Moilanen E; Leinonen E; Kampman O
    Psychiatry Res; 2021 Dec; 306():114227. PubMed ID: 34610543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced weight gain: a review of the literature.
    Allison DB; Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 7():22-31. PubMed ID: 11346192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.
    Malhotra AK; Correll CU; Chowdhury NI; Müller DJ; Gregersen PK; Lee AT; Tiwari AK; Kane JM; Fleischhacker WW; Kahn RS; Ophoff RA; Meltzer HY; Lencz T; Kennedy JL
    Arch Gen Psychiatry; 2012 Sep; 69(9):904-12. PubMed ID: 22566560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic drugs: the weight problem.
    Harv Ment Health Lett; 2000 Dec; 17(6):6-8. PubMed ID: 11114878
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of weight gain in patients with schizophrenia.
    Aquila R
    J Clin Psychiatry; 2002; 63 Suppl 4():33-6. PubMed ID: 11913674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.